We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Horizon Discovery Sign License Agreement with Ortho Biotech Oncology Research & Development
News

Horizon Discovery Sign License Agreement with Ortho Biotech Oncology Research & Development

Horizon Discovery Sign License Agreement with Ortho Biotech Oncology Research & Development
News

Horizon Discovery Sign License Agreement with Ortho Biotech Oncology Research & Development

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Horizon Discovery Sign License Agreement with Ortho Biotech Oncology Research & Development"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Horizon Discovery (Horizon) has announced it has signed a commercial agreement with Janssen Pharmaceutica NV, relating to its X-MAN technology.

Horizon’s X-MAN (Mutant And Normal) cell-line technology provides the first genetically-defined and patient-relevant in vitro models of human cancer. These models are being used by a growing number of Pharma and Biotech companies to rationalize key steps of the ‘targeted’ drug development process, and thus accelerate and economize the burgeoning field of ‘personalized’ medicine.

The agreement covers the licensing of certain X-MAN cell lines including major cancer causing genes and their matched normal genetic backgrounds. The approach should enable J&J to gather information relating to the selectivity and mode-of-action of their compounds using model in-vitro systems.

“Dr Darrin M Disley, Chairman of Horizon says “it has always been our aim to work with leading players in the Rx and Dx space and we hope to build a long and productive relationship moving forward”

Janssen Pharmaceutica NV will pay Horizon undisclosed up-front and renewal fees during the term of the agreement. Work between the parties will begin in August 2009.
Advertisement